Yiqun Sun

Yiqun Sun

Auto-generated profile, based on publicly available information

Yiqun Sun

Department of Radiology, Fudan University Shanghai Cancer Center, 270 Dongan Rd, Shanghai 200032, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2018 in Diagnostic and Interventional Radiology
Verified
Journal Article
Closed access
YSYiqun Sun
Yiqun Sun
JLJianwen Li
Jianwen Li
LSLijun Shen
Lijun Shen
XWXiaolin Wang
Xiaolin Wang
TTTong Tong
Tong Tong
YGYajia Gu
Yajia Gu
Diagnostic and Interventional Radiology

12 November 2022 in EPMA Journal
Verified
Journal Article
Open access
PDF file
ZLZonglin Liu
Zonglin Liu
YWYueming Wang
Yueming Wang
FSFu Shen
Fu Shen
ZZZhiyuan Zhang
Zhiyuan Zhang
JGJing Gong
Jing Gong
TTTong Tong
Tong Tong
Background: Currently, the rate of recurrence or metastasis (ROM) remains high in rectal cancer (RC) patients treated with the standard regimen. The potential of diffusion-weighted imaging (DWI) in predicting ROM risk has been reported, but the efficacy is insufficient. Aims: This study investigated the potential of a new sequence called readout-segmented echo-planar imaging (RS-EPI) DWI in predicting the ROM risk of patients with RC using machine learning methods to achieve the principle of predictive, preventive, and personalized medicine (PPPM) application in RC treatment. Methods: A total of 195 RC patients from two centres who directly received total mesorectal excision were retrospectively enrolled in our study. Machine learning methods, including recursive feature elimination (RFE), the synthetic minority oversampling technique (SMOTE), and the support vector machine (SVM) classifier, were used to construct models based on clinical-pathological factors (clinical model), radiomic features from RS-EPI DWI (radiomics model), and their combination (merged model). The Harrell concordance index (C-index) and the area under the time-dependent receiver operating characteristic curve (AUC) were calculated to evaluate the predictive performance at 1 year, 3 years, and 5 years. Kaplan‒Meier analysis was performed to evaluate the ability to stratify patients according to the risk of ROM. Findings: The merged model performed well in predicting tumour ROM in patients with RC at 1 year, 3 years, and 5 years in both cohorts (AUC = 0.887/0.813/0.794; 0.819/0.795/0.783) and was significantly superior to the clinical model (AUC = 0.87 [95% CI: 0.80–0.93] vs. 0.71 [95% CI: 0.59–0.81], p = 0.009; C-index = 0.83 [95% CI: 0.76–0.90] vs. 0.68 [95% CI: 0.56–0.79], p = 0.002). It also had a significant ability to differentiate patients with a high and low risk of ROM (HR = 12.189 [95% CI: 4.976–29.853], p < 0.001; HR = 6.427 [95% CI: 2.265–13.036], p = 0.002). Conclusion: Our developed merged model based on RS-EPI DWI accurately predicted and effectively stratified patients with RC according to the ROM risk at an early stage with an individualized profile, which may be able to assist physicians in individualizing the treatment protocols and promote a meaningful paradigm shift in RC treatment from traditional reactive medicine to PPPM.

30 September 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
FXFan Xia
Fan Xia
YCYajie Chen
Yajie Chen
DZDi Zhou
Di Zhou
JWJuefeng Wan
Juefeng Wan
LSLijun Shen
Lijun Shen
Xinxiang LiXinxiang Li
Xinxiang Li
Purpose: Organ preservation (OP) can be preferred in low-lying rectal cancer to reduce morbidity from radical surgery. Immunotherapy-based total neoadjuvant therapy (iTNT) showed remarkable tumor regression and facilitated OP in locally advanced rectal cancer. This study evaluated the efficacy and safety of iTNT, comprising short-course radiotherapy followed by CAPOX and toripalimab, in enabling OP for early low rectal cancer. Patients and Methods: TORCH-E was a multicenter, single-arm phase II trial enrolling patients with T2–3bN0 rectal adenocarcinoma ≤5 cm from the anal verge. Patients received short-course radiotherapy (25 Gy/5 Fx) followed by four cycles of CAPOX plus toripalimab. Good responders were eligible for watch-and-wait (WW) or local excision (LE), and total mesorectal excision was recommended for poor responders or those with high-risk features after LE. The primary endpoint was complete response (CR), including clinical CR with WW and pathologic CR. Secondary endpoints included OP rate, adverse effects, and quality of life. Results: From December 2022 to March 2024, 33 patients were enrolled, with 75.8% staged as T3. After iTNT, 16 patients achieved clinical CR and adopted WW. Pathologic CR was observed in eight of eight LE and five of nine patients who underwent total mesorectal excision. The most common grade 3 to 4 adverse event was thrombocytopenia (27.3%). After a median follow-up of 24.1 months, four local regrowths and one metastatic recurrence occurred. The total CR rate was 72.7%, and the OP rate was 60.6%. Conclusions: As an exploratory trial, TORCH-E demonstrated a promising iTNT approach achieving a high CR rate, enabling OP through WW and selective LE in early low rectal cancer, warranting subsequent randomized validation.

21 November 2017 in British Journal of Radiology
Verified
Journal Article
Closed access
LSLijun Shen
Lijun Shen
YSYiqun Sun
Yiqun Sun
HZHui Zhang
Hui Zhang
JZJing Zhang
Jing Zhang
WDWeijuan Deng
Weijuan Deng
ZZZhen Zhang
Zhen Zhang
Objective: To evaluate the feasibility of the EMD (extramural depth)/mesorectum ratio as a marker for T3 rectal cancer and its ability to predict tumour response to neoadjuvant chemoradiation and survival. Methods: From 2010 to 2016, 284 T3 rectal cancer patients who underwent high resolution MRI before neoadjuvant chemoradiation were enrolled. The EMD was defined as the distance from the outer edge of the muscularis propria to the outermost edge of the tumour. The measurement of the tumour EMD and mesorectum was in the same layer and their ratio was calculated. Receiver operating characteristic analysis and relative area under the curve statistics were used to choose the cut-off value. The association of the EMD/mesorectum ratio and other MRI or clinical factors with the tumour regression grade (TRG) was analysed. Cox regression analysis was used to estimate independent risk factors for disease-free survival (DFS) and overall survival (OS). Results: The mean EMD/mesorectum ratio was 0.47 ± 0.3. We chose an EMD/mesorectum ratio of 0.5 in further analyses after receiver operating characteristic analysis. Of 284 patients, 177 (62.3%) had an EMD/mesorectum ratio ≤ 0.5. Patients with an EMD/mesorectum ratio ≤ 0.5 had a higher TRG 0–1 rate than patients with a ratio >0.5 (53.1% vs 36.4%, p = 0.006). A multivariate analysis identified that an EMD/mesorectum ratio >0.5 [hazard ratio (HR) 2.020; p = 0.028] and ypTNM II-III (HR 3.550; p = 0.017) were independent prognostic factors to indicate decreased DFS. For OS, only patients with TRG 2–3 had decreased OS compared with patients with TRG 0–1 (HR 2.959; p = 0.035). Conclusion: When the EMD/mesorectum ratio was applied to categorize T3 rectal cancer patients, the ratio of 0.5 can be used as a cut-off value for T3 rectal cancer. Patients with a ratio ≤ 0.5 had a higher response rate and better DFS. However, further validation is needed in a larger sample of patients. Advances in knowledge: The EMD/mesorectum ratio may serve to predict tumour response to neoadjuvant chemoradiation and survival in T3 rectal cancer patients.

1 May 2025 in Radiology: Imaging Cancer
Verified
Journal Article
Open access
ZLZonglin Liu
Zonglin Liu
RMRunqi Meng
Runqi Meng
QMQiong Ma
Qiong Ma
ZGZhen Guan
Zhen Guan
RLRong Li
Rong Li
DSDinggang Shen
Dinggang Shen
MultiRecNet, a fully automatic multitask deep learning network, accurately predicted disease-free survival in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy, using multimodal MRI.

7 April 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
XHXiaoxin Hu
Xiaoxin Hu
JLJianwen Li
Jianwen Li
YSYinan Sun
Yinan Sun
YSYiqun Sun
Yiqun Sun
TTTong Tong
Tong Tong
Purpose: The purpose of the study was to assess the ability of percentage of tumor invasion (PTI) of T3 rectal cancer on pretreatment MRI as an imaging biomarker to reflect aggressiveness and to predict tumor response after neoadjuvant chemoradiation (NCRT) in Chinese population.Methods: A total of 107 Chinese rectal cancer patients who underwent pretreatment MRI staging as T3 were included. The extramural depth of tumor invasion (EMD), the distance between outer border of muscularis propria (MP) and mesorectal fascia (MRF) we called “thickness of the mesorectum (TM)”) at the same slice and direction were measured at pretreatment MRI, and PTI was equal to EMD/TM, was calculated. The EMD and PTI of subgroups based on pretreatment CEA, CA19-9 levels; N category and pathological complete response (pCR) were compared. The parameters, which described tumor invasion, were compared between pCR and non-pCR group. Student t-tests and logistic analysis were applied.Results: The pretreatment PTI was higher in CEA ≥5.2 ng/ml patients (58.52% ± 27.68%) than in CEA <5.2 ng/ml patients (47.27% ± 24.15%) (p = 0.034). The pretreatment EMD in non-pCR group (7.21 ± 2.85 mm) was higher than in pCR group (6.14 ± 3.56 mm) (p = 0.049). The pretreatment PTI in non-pCR group (57.4% ± 26.4%) was higher than in pCR group (47.3% ± 29.1%) (p = 0.041). Compared with patients with PTI ≥50%, MRF (+), more patients with PTI <50%, MRF (−) showed pCR (OR = 8.44, p = 0.005; OR = 6.32, p = 0.024).Conclusion: The PTI obtained at pretreatment MRI may serve as an imaging biomarker to reflect tumor aggressiveness and predict which T3 rectal cancer patients may benefit from NCRT in Chinese population.